PepGen (PEPG) Stock Forecast, Price Target & Predictions
PEPG Stock Forecast
PepGen stock forecast is as follows: an average price target of $29.50 (represents a 712.67% upside from PEPG’s last price of $3.63) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
PEPG Price Target
The average price target for PepGen (PEPG) is $29.50 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $33.00 to $26.00. This represents a potential 712.67% upside from PEPG's last price of $3.63.
PEPG Analyst Ratings
According to 2 Wall Street analysts, PepGen's rating consensus is 'Buy'. The analyst rating breakdown for PEPG stock is 0 'Strong Buy' (0.00%), 1 'Buy' (50.00%), 1 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
PepGen Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Dec 21, 2022 | H.C. Wainwright | $26.00 | $14.51 | 79.19% | 616.25% | |
| Nov 10, 2022 | Leerink Partners | $33.00 | $12.50 | 164.00% | 809.09% |
The latest PepGen stock forecast, released on Dec 21, 2022 by H.C. Wainwright company, set a price target of $26.00, which represents a 79.19% increase from the stock price at the time of the forecast ($14.51), and a 616.25% increase from PEPG last price ($3.63).
PepGen Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $3.63 | $3.63 | $3.63 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of PepGen stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to PepGen's last price of $3.63. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 18, 2024 | Bank of America Securities | Neutral | Neutral | Hold |
| Nov 10, 2022 | SVB Leerink | Outperform | Outperform | Hold |
| May 31, 2022 | Bank of America Securities | Buy | Initialise |
PepGen's last stock rating was published by Bank of America Securities on Nov 18, 2024. The company gave PEPG a "Neutral" rating, the same as its previous rate.
PepGen Financial Forecast
PepGen Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
PepGen's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. PEPG's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
PepGen EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict PEPG's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than PepGen's previous annual EBITDA (undefined) of $NaN.
PepGen Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-25.25M | $-24.44M | $-23.78M | $-22.97M | $-26.52M | $-28.30M | $-23.44M |
| High Forecast | $-25.25M | $-24.44M | $-23.78M | $-21.03M | $-20.30M | $-28.30M | $-23.44M |
| Low Forecast | $-25.25M | $-24.44M | $-23.78M | $-24.59M | $-34.38M | $-28.30M | $-23.44M |
| Surprise % | - | - | - | - | - | - | - |
PepGen's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. PEPG's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
PepGen SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
PepGen's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to PEPG last annual SG&A of $NaN (undefined).
PepGen EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.78 | $-0.75 | $-0.73 | $-0.70 | $-0.81 | $-0.87 | $-0.72 |
| High Forecast | $-0.78 | $-0.75 | $-0.73 | $-0.65 | $-0.62 | $-0.87 | $-0.72 |
| Low Forecast | $-0.78 | $-0.75 | $-0.73 | $-0.75 | $-1.06 | $-0.87 | $-0.72 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, PepGen's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to PEPG previous annual EPS of $NaN (undefined).
PepGen Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PEPG | PepGen | $4.30 | $29.50 | 586.05% | Buy |
| VIGL | Vigil Neuroscience | $1.73 | $11.00 | 535.84% | Buy |
| MOLN | Molecular Partners | $5.25 | $29.00 | 452.38% | Buy |
| CCCC | C4 Therapeutics | $4.05 | $20.00 | 393.83% | Buy |
| IPSC | Century Therapeutics | $1.17 | $5.00 | 327.35% | Buy |
| PMVP | PMV Pharmaceuticals | $1.52 | $6.00 | 294.74% | Buy |
| ANTX | AN2 Therapeutics | $1.34 | $5.00 | 273.13% | Buy |
| CMPX | Compass Therapeutics | $1.53 | $5.00 | 226.80% | Buy |
| CGEM | Cullinan Oncology | $11.49 | $34.00 | 195.91% | Buy |
| PRTC | PureTech Health | $21.80 | $57.00 | 161.47% | Buy |
| MLYS | Mineralys Therapeutics | $12.35 | $30.00 | 142.91% | Buy |
| PHVS | Pharvaris | $18.49 | $42.00 | 127.15% | Buy |
| TYRA | Tyra Biosciences | $15.22 | $31.75 | 108.61% | Buy |
| EWTX | Edgewise Therapeutics | $30.17 | $46.25 | 53.30% | Buy |
| TRDA | Entrada Therapeutics | $18.45 | $20.00 | 8.40% | Buy |